Lonza Group (OTCMKTS:LZAGY – Get Free Report) was upgraded by investment analysts at Redburn Atlantic to a “strong-buy” rating in a research report issued on Wednesday,Zacks.com reports.
Separately, The Goldman Sachs Group raised shares of Lonza Group to a “strong-buy” rating in a report on Wednesday, October 9th.
Read Our Latest Stock Analysis on LZAGY
Lonza Group Trading Up 2.4 %
About Lonza Group
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments.
Featured Articles
- Five stocks we like better than Lonza Group
- What Are Trending Stocks? Trending Stocks Explained
- ServiceNow: Will the High-Flyer Finally Split in 2024?
- Golden Cross Stocks: Pattern, Examples and Charts
- MarketBeat Week in Review – 11/25 – 11/29
- The 3 Best Retail Stocks to Shop for in August
- These 3 Stocks Are Heavy Hitters in Alternative Asset Management
Receive News & Ratings for Lonza Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group and related companies with MarketBeat.com's FREE daily email newsletter.